• In recent updates, Northrop Grumman reported a record backlog of US$95.61 billion, highlighted improved economics on its B‑21 bomber program, and reaffirmed full‑year sales and earnings guidance despite an operating cash outflow in the first quarter of 2026.
• Beyond headline backlog growth, the shift of the B‑21 program from loss to operating income suggests maturing execution on one of Northrop Grumman’s most critical long‑cycle defense platforms.
• Next, we’ll examine how the record US$95.61 billion backlog and B‑21 progress might influence Northrop Grumman’s existing investment narrative.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Northrop Grumman Investment Narrative Recap

To own Northrop Grumman, you need to believe that its large, long-cycle U.S. defense programs can translate strong funded demand and program execution into resilient earnings, despite their concentration risk. The latest record US$95.61 billion backlog and the B‑21’s move into positive operating income support the near term catalyst around execution and margin delivery, while the biggest current risk remains heavy reliance on these flagship programs and U.S. budget decisions. Overall, this news does not fundamentally change that trade off.

The most relevant update here is the B‑21 Raider progress, including extensive flight testing and digital manufacturing investments alongside new Air Force agreements. This aligns directly with the short term focus on B‑21 and Sentinel as key margin and earnings drivers, and the shift from loss to operating income suggests the B‑21 is moving further along that path, even as Northrop Grumman continues to invest heavily in capacity and infrastructure that must be absorbed by future awards.

Yet investors should also be aware of how dependent this story is on a few very large U.S. programs and...

Northrop Grumman’s narrative projects $50.0 billion revenue and $4.6 billion earnings by 2029. This requires 5.7% yearly revenue growth, with earnings expected to stay flat, resulting in no change from current earnings of $4.6 billion.

Uncover how Northrop Grumman's forecasts yield a $696.95 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$523.62 to US$696.95, showing how far apart individual views can be. Against this backdrop, the concentration of Northrop Grumman’s outlook in major U.S. programs like B 21 and Sentinel gives those differing opinions real weight for how you think about the company’s future performance.

Explore 3 other fair value estimates on Northrop Grumman - why the stock might be worth just $523.62!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Northrop Grumman research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Northrop Grumman research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Northrop Grumman's overall financial health at a glance.

Contemplating Other Strategies?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 29 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.